Micronised tissue allografts - MiMedx

Drug Profile

Micronised tissue allografts - MiMedx

Alternative Names: Dehydrated human amnion/chorion membrane - MiMedx; dHACM

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator MiMedx
  • Class Anti-inflammatories; Cell therapies; Tissue extracts
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inflammation; Wounds
  • Clinical Phase Unknown Shoulder injuries
  • Preclinical Ischaemia

Most Recent Events

  • 01 Feb 2017 Clinical trials in Shoulder injuries in USA (Topical) (NCT03084068)
  • 29 Aug 2016 MiMedx has patent protection for amniotic membrane allografts and CollaFixTM in USA
  • 01 Jun 2016 MiMedx completes a clinical trial in Diabetic foot ulcer (Treatment-experienced) in Canada (NCT02587104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top